The phenotype of polycythemia due to Croatian homozygous VHL (571C>G:H191D) mutation is different from that of Chuvash polycythemia (VHL 598C>T:R200W)

Mutations of VHL (a negative regulator of hypoxia-inducible factors) have position-dependent distinct cancer phenotypes. Only two known inherited homozygous VHL mutations exist and they cause polycythemia: Chuvash R200W and Croatian H191D. We report a second polycythemic Croatian H191D homozygote distantly related to the first propositus. Three generations of both families were genotyped for analysis of shared ancestry. Biochemical and molecular tests were performed to better define their phenotypes, with an emphasis on a comparison with Chuvash polycythemia. The VHL H191D mutation did not segregate in the family defined by the known common ancestors of the two subjects, suggesting a high prevalence in Croatians, but haplotype analysis indicated an undocumented common ancestor ∼six generations ago as the founder of this mutation. We show that erythropoietin levels in homozygous VHL H191D individuals are higher than in VHL R200W patients of similar ages, and their native erythroid progenitors, unlike Chuvash R200W, are not hypersensitive to erythropoietin. This observation contrasts with a report suggesting that polycythemia in VHL R200W and H191D homozygotes is due to the loss of JAK2 regulation from VHL R200W and H191D binding to SOCS1. In conclusion, our studies further define the hematologic phenotype of VHL H191D and provide additional evidence for phenotypic heterogeneity associated with the positional effects of VHL mutations.

[1]  T. Ganz,et al.  The heterozygote advantage of the Chuvash polycythemia VHLR200W mutation may be protection against anemia , 2011, Haematologica.

[2]  William Y. Kim,et al.  Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia , 2011, Nature Medicine.

[3]  H. Moch,et al.  VHL gene mutations and their effects on hypoxia inducible factor HIFα: identification of potential driver and passenger mutations. , 2011, Cancer research.

[4]  S. Richard,et al.  von Hippel–Lindau disease: A clinical and scientific review , 2011, European Journal of Human Genetics.

[5]  Xin Wu,et al.  Abstract 5500: Inhibition of poly(ADP-ribose) polymerase in lung cancer cells with defective Fanconi anemia (FA) pathway , 2011 .

[6]  Jinchuan Xing,et al.  Maximum-likelihood estimation of recent shared ancestry (ERSA). , 2011, Genome research.

[7]  M. Percy,et al.  The HIF pathway and erythrocytosis. , 2011, Annual review of pathology.

[8]  Brian L. Browning,et al.  High-resolution detection of identity by descent in unrelated individuals. , 2010, American journal of human genetics.

[9]  Catherine L. Worth,et al.  Structural bioinformatics mutation analysis reveals genotype–phenotype correlations in von Hippel‐Lindau disease and suggests molecular mechanisms of tumorigenesis , 2009, Proteins.

[10]  Heinz Ludwig,et al.  Anemia management in oncology and hematology. , 2009, The oncologist.

[11]  W. Rathmell,et al.  von Hippel-Lindau mutation in mice recapitulates Chuvash polycythemia via hypoxia-inducible factor-2alpha signaling and splenic erythropoiesis. , 2007, The Journal of clinical investigation.

[12]  Zhaohui S. Qin,et al.  A second generation human haplotype map of over 3.1 million SNPs , 2007, Nature.

[13]  J. Prchal,et al.  In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2 V617F allele. , 2007, Experimental hematology.

[14]  S. Perrotta,et al.  Von Hippel-Lindau – dependent polycythemia is endemic on the island of Ischia : identification of a novel cluster , 2005 .

[15]  W. Kaelin,et al.  Role of VHL gene mutation in human cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  P. Choyke,et al.  Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors. , 2004, Blood.

[17]  S. Shete,et al.  The worldwide distribution of the VHL 598C>T mutation indicates a single founding event. , 2004, Blood.

[18]  S. Thein,et al.  Erythrocytosis and the Chuvash von Hippel‐Lindau mutation , 2003, British journal of haematology.

[19]  J. Prchal,et al.  Mutations of von Hippel-Lindau tumor-suppressor gene and congenital polycythemia. , 2003, American journal of human genetics.

[20]  W. Kaelin,et al.  HIF hydroxylation and the mammalian oxygen-sensing pathway. , 2003, The Journal of clinical investigation.

[21]  J. Jelinek,et al.  Mutations in the VHL gene in sporadic apparently congenital polycythemia. , 2003, Blood.

[22]  David Mole,et al.  Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia , 2002, Nature Genetics.

[23]  G. Horgan,et al.  Relative expression software tool (REST©) for group-wise comparison and statistical analysis of relative expression results in real-time PCR , 2002 .

[24]  J. Prchal,et al.  Congenital polycythemia in Chuvashia. , 1997, Blood.

[25]  Alexander Gusev,et al.  Whole population, genome-wide mapping of hidden relatedness. , 2009, Genome research.

[26]  K. Schwarz,et al.  Mutations in the von Hippel-Lindau (VHL) tumor suppressor gene and VHL-haplotype analysis in patients with presumable congenital erythrocytosis. , 2005, Haematologica.

[27]  R. Gatti,et al.  Congenital polycythemia with homozygous and heterozygous mutations of von Hippel-Lindau gene: five new Caucasian patients. , 2005, Haematologica.

[28]  J. Minna,et al.  Antioncogenes and human cancer. , 1993, Annual review of medicine.